Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07130994Not ApplicableNot Yet Recruiting

Reduction of Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)

Role: lead

NCT06414265Not ApplicableRecruiting

Reduction of Mitral Regurgitation With the SATURN Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) System in Patients With Severe Symptomatic Mitral Regurgitation

Role: lead

NCT04464876Not ApplicableUnknown

SATURN Transcatheter Mitral Valve Replacement for Functional Mitral Regurgitation

Role: lead

All 3 trials loaded